References
Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854–861.
Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008;28:1053–1060
Chen E, Hsu J, Park CH. Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009;40:68–70.
Ganssauge M, Wilhelm H, Bartz-Schmidt KU, Aisenbrey S. Nonarteritic anteriorischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin®) for treatment of angoid streaks in pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 2009;247:1707–1710.
Chung EJ, Roh MI, Kwon OW, Koh HJ. Effect of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008;28:957–963.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Huang, J.Y., Ozaki, H., Hayashi, H. et al. Anterior ischemic optic neuropathy following intravitreal bevacizumab. Jpn J Ophthalmol 54, 252–254 (2010). https://doi.org/10.1007/s10384-009-0790-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-009-0790-4